Provention Bio Inc Equity-NMS: PRVB

Healthcare

Biotechnology

Buy/Sell an entire stock
or a fraction.

Vested

Already an existing customer?

New User?

Open Your Free Demat Account And Start Trading Seamlessly

Loading, Please wait...

Error in Fetching Data, Please retry later.

No data available.

Previous close :

$24.23

5Y :

63.27%

What is the share price of Provention Bio Inc today?

Provention Bio Inc (PRVB) share price as of October 8, 2025, is $24.98. If you are investing from India, you can always check the valuation in the INR before investing.

Can Indian Investors purchase shares of Provention Bio Inc?

Yes, Indian Investors can invest in the Provention Bio Inc (PRVB) Share by opening an international trading account with Angel One.

How can I purchase Provention Bio Inc shares in India?

Purchasing Provention Bio Inc (PRVB) share from India can be done by:

Directly: By opening an international trading account with Angel One. The process would include KYC verification.
The account activation takes a few minutes to a few hours, after which you can start buying Provention Bio Inc (PRVB) by making deposits in US dollars.
Indirectly: By investing in mutual funds and Exchange Traded Funds (ETF) that offers exposure in global stocks.

Can I buy Fractional shares of Provention Bio Inc?

Yes, you can purchase fractional shares of Provention Bio Inc (PRVB) or any other US company shares in Angel One for any dollar amount.

What is the market capitalization value of Provention Bio Inc?

The market capitalization of Provention Bio Inc on October 8, 2025, is $0.

In which sector Provention Bio Inc belongs?

Provention Bio Inc operates in the Healthcare sector, specifically in the Biotechnology industry.

What documents are required to invest in Provention Bio Inc stocks?

In order to invest in Provention Bio Inc (PRVB) you will need Proof of Identification (Aadhaar, PAN, Passport etc.) and Proof of Address (Aadhaar, Voter Card etc.)

From start to end, the process is digital and can be seamless.

Provention Bio, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on advancing the development and commercialization of investigational therapies that intercept and prevent debilitating and life-threatening immune-mediated diseases. The Company’s pipeline includes TZIELD (teplizumab-mzwv), PRV-3279, Ordesekimab and PRV-101. TZIELD (teplizumab-mzwv) is a CD3-directed antibody indicated to delay the onset of stage three T1D in adults and pediatric patients aged eight years and older with stage two T1D. It is also developing TZIELD for use in stage three newly diagnosed T1D patients. PRV-3279 is a humanized bispecific scaffold molecule targeting the B-cell surface proteins for the treatment of SLE and for the prevention of immunogenicity of biotherapeutics. Ordesekimab is a human anti-interleukin 15 (IL-15) monoclonal antibody for the treatment of gluten-free diet non-responsive celiac disease. PRV-101 is a CVB vaccine to prevent acute CVB infections.